Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients

NCT00640328 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Sclerosis

Interventions

DRUG: Ofatumumab 100
DRUG: Ofatumumab 300
DRUG: Ofatumumab 700
DRUG: Placebo

Sponsor

GlaxoSmithKline